Novo Nordisk shares up on promise of latest obesity asset

11 September 2024

Shares in Novo Nordisk (NOV: N) frequently jump upwards when the latest data on the company’s blockbuster obesity drug Wegovy (semaglutide) are released.

But Wednesday’s rise of around 2% in the company’s market value can be attributed to another obesity drug being developed by the Danish drugmaker.

While Wegovy is a GLP-1 receptor agonist, mimicking the action of the gut hormone GLP-1, amycretin mimics the action of two peptide hormones in one single molecule. The latter is both an amylin and GLP-1 receptor agonist. Both of these play a key role in appetite regulation and a feeling of hunger, and have been shown to lead to weight loss.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK